Results 101 to 110 of about 51,615 (305)

Different loss of material in recurrent chromosome 20 interstitial deletions in Shwachman-Diamond syndrome and in myeloid neoplasms [PDF]

, 2013
BACKGROUND: An interstitial deletion of the long arms of chromosome 20, del(20)(q), is frequent in the bone marrow (BM) of patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms (MPN), and it is ...
Lo Curto F, Mare L, Marletta C, Maserati E, Montalbano G, Pasquali F, Pressato B, Valli R   +7 more
core   +1 more source

Peripheral versus Marrow Lipidomics in Patients with Severe Aplastic Anemia: Potential Indicators for Early Immunosuppressive Treatment Response

Lipids, EarlyView.
ABSTRACT This study aimed to explore the differences of peripheral blood (PB) and bone marrow serum lipidomic profiles in severe aplastic anemia (SAA) patients and their significance in predicting earlier immunosuppressive therapy (IST) response. A cohort of 11 newly diagnosed SAA patients and 15 healthy controls were enrolled between June 2020 and ...
Zexing Sun, Yilei Hong, Yaonan Hong, Chuanao Xin, Qi Liu, Huijin Hu, Yingying Shen, Ying Chen, Shan Liu, Yiping Shen, Yuhong Zhou, Dijiong Wu   +11 more
wiley   +1 more source

The role of toll-like receptors in hematopoietic malignancies [PDF]

, 2016
Toll-like receptors (TLRs) are a family of pattern recognition receptors (PRRs) that shape the innate immune system by identifying pathogen-associated molecular patterns (PAMPS) and host-derived damage associated molecular patterns (DAMPS).
Bhatt, Sima T, Monlish, Darlene A, Schuettpelz, Laura G   +2 more
core   +3 more sources

Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy

Medicine Bulletin, EarlyView.
ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley   +1 more source

Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group

Haematologica, 2017
Current recommendations for diagnosing myelodysplastic syndromes endorse flow cytometry as an informative tool. Most flow cytometry protocols focus on the analysis of progenitor cells and the evaluation of the maturing myelomonocytic lineage.
Theresia M. Westers, Eline M.P. Cremers, Uta Oelschlaegel, Ulrika Johansson, Peter Bettelheim, Sergio Matarraz, Alberto Orfao, Bijan Moshaver, Lisa Eidenschink Brodersen, Michael R. Loken, Denise A. Wells, Dolores Subirá, Matthew Cullen, Jeroen G. te Marvelde, Vincent H.J. van der Velden, Frank W.M.B. Preijers, Sung-Chao Chu, Jean Feuillard, Estelle Guérin, Katherina Psarra, Anna Porwit, Leonie Saft, Robin Ireland, Timothy Milne, Marie C. Béné, Birgit I. Witte, Matteo G. Della Porta, Wolfgang Kern, Arjan A. van de Loosdrecht   +28 more
doaj   +1 more source

Pediatric Myelodysplastic Syndromes [PDF]

Journal of Hematopathology, 2015
Pediatric myelodysplastic syndromes (MDS) are a group of rare clonal hematopoietic stem cell disorders characterized by varying degree of cytopenias, ineffective and dysplastic hematopoiesis, and the risk of leukemic transformation. The clinical, laboratory, and histologic presentation of pediatric MDS shares significant overlap with other inherited ...
openaire   +1 more source

Engineering Dosimetric Excellence In Total Body Irradiation: Tomotherapy‐Driven Protocols for Precision and Reproducibility

Precision Radiation Oncology, EarlyView.
• Objective: Assess helical Tomotherapy‐based TBI for clinical feasibility, dosimetric reproducibility, and in‐vivo accuracy using dual‐orientation simulation and patient‐specific QA. • Methodology: Implementation of ArcCHECK 3D diode array, ionization chamber verification, and in‐vivo dosimetry with OSLDs at 16 anatomical sites to ensure precise dose ...
Sandeep Singh, Dipesh, Supratik Sen, Abhay Kumar Singh, Mahipal, Manindra Bhushan, Jaskaran Singh Sethi, David K. Simson, Munish Gairola   +8 more
wiley   +1 more source

Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)

Haematologica, 2011
Background Anemia is an established negative prognostic factor in myelodysplastic syndromes but the relationship between its degree and clinical outcome is poorly defined.
Luca Malcovati, Matteo G. Della Porta, Corinna Strupp, Ilaria Ambaglio, Andrea Kuendgen, Kathrin Nachtkamp, Erica Travaglino, Rosangela Invernizzi, Cristiana Pascutto, Mario Lazzarino, Ulrich Germing, Mario Cazzola   +11 more
doaj   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party

Haematologica, 2014
Acquired chromosomal abnormalities are important prognostic factors in patients with myelodysplastic syndromes treated with supportive care and with disease-modifying therapeutic interventions, including allogeneic hematopoietic stem cell transplantation.
Francesco Onida, Ronald Brand, Anja van Biezen, Michel Schaap, Peter A. von dem Borne, Johan Maertens, Dietrich W. Beelen, Enric Carreras, Emilio P. Alessandrino, Liisa Volin, Jürgen H.E. Kuball, Angela Figuera, Jorge Sierra, Jürgen Finke, Nicolaus Kröger, Theo de Witte   +15 more
doaj   +1 more source